

10/534,650

=> file caplus

FILE 'CAPLUS' ENTERED AT 15:24:01 ON 24 OCT 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Oct 2006 VOL 145 ISS 18


FILE LAST UPDATED: 23 Oct 2006 (20061023/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> d que

L1 STR



Structure attributes must be viewed using STN Express query preparation.

L3 7 SEA FILE=REGISTRY SSS FUL L1

L4 1 SEA FILE=CAPLUS L3

=> d l4 ibib abs hitstr

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:453210 CAPLUS

DOCUMENT NUMBER: 141:23428

TITLE: Preparation of benzofuran derivatives for treatment of glucokinase-mediated disease

INVENTOR(S): McKerrecher, Darren; Rayner, John Wall

PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.; Astrazeneca Uk Limited

SOURCE: PCT Int. Appl., 41 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004046139	A1	20040603	WO 2003-GB4919	20031113
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,  
 GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,  
 LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,  
 OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
 TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,  
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,  
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003282234 A1 20040615 AU 2003-282234 20031113  
 EP 1578745 A1 20050928 EP 2003-773852 20031113  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 JP 2006509749 T2 20060323 JP 2004-552856 20031113  
 US 2006058353 A1 20060316 US 2005-534650 20050512  
 PRIORITY APPLN. INFO.: GB 2002-26930 A 20021119  
 WO 2003-GB4919 W 20031113

OTHER SOURCE(S): MARPAT 141:23428  
 GI




AB Title compds. I [wherein ring A = (un)substituted pyridin-2-yl, thiazol-2-yl; R1, R2 = independently H, alkyl; R3 = alkyl, alkoxy, carbocyclyl, carbocyclyloxy, heterocyclyl, heterocyclyloxy; and their salts, prodrugs, or solvates, together with a pharmaceutically acceptable diluent or carrier thereof] were prepared for the treatment of glucokinase-mediated disease. For example, 2-methyl-4-isobutoxy-6-[N-(5-carboxypyridin-2-yl)carbamoyl]benzofuran was prepared in multi-steps reactions starting from the reaction of 5-methylfuran-2'-al with 1-methoxycarbonyl-2-tert-butoxycarbonylethylphosphorane. The pharmaceutical compns. of the prepared compds. were presented. Thus, I and their pharmaceutical compns. are useful for the treatment or prevention of a disease or medical conditions mediated through glucokinase (no data).

IT 697748-08-6P 697748-09-7P 697748-11-1P  
 697748-12-2P 697748-13-3P 697748-14-4P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of benzofuran derivs. for treatment of glucokinase-mediated disease)


RN 697748-08-6 CAPLUS  
 CN 3-Pyridinecarboxylic acid, 6-[[[2-methyl-4-(2-methylpropoxy)-6-benzofuranyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

10/534,650




RN 697748-09-7 CAPLUS

CN 3-Pyridinecarboxylic acid, 6-[[[4-[(2-fluorophenyl)methoxy]-2-methyl-6-benzofuranyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 697748-11-1 CAPLUS


CN 3-Pyridinecarboxylic acid, 6-[[[2-methyl-4-[(5-methyl-3-isoxazolyl)methoxy]-6-benzofuranyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 697748-12-2 CAPLUS


CN 3-Pyridinecarboxylic acid, 6-[[[4-[(2-fluorophenyl)methoxy]-6-benzofuranyl]carbonyl]amino]- (9CI) (CA INDEX NAME)

10/534,650




RN 697748-13-3 CAPLUS

CN 3-Pyridinecarboxylic acid, 6-[[[4-[(5-methyl-3-isoxazolyl)methoxy]-6-benzofuranyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 697748-14-4 CAPLUS

CN 3-Pyridinecarboxylic acid, 6-[[[2-methyl-4-[2-(3-thienyl)ethoxy]-6-benzofuranyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



IT 697748-16-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of benzofuran derivs. for treatment of glucokinase-mediated

10/534,650

disease)

RN 697748-16-6 CAPLUS

CN 3-Pyridinecarboxylic acid, 6-[[[2-methyl-4-(2-methylpropoxy)-6-benzofuranyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



=>